Biogen Inc (OQ:BIIB)

Sector:  Healthcare Industry:  Pharmaceuticals
 
See Regulatory Filings on SEC
Company Contact
Address: 225 Binney Street
CAMBRIDGE MA 02142
Tel: N/A
Website: https://www.biogen.com
IR: See website
<
Key People
Christopher A. Viehbacher
President, Chief Executive Officer, Director
Charles E. Triano
Senior Vice President, Head of Investor Relations
Michael R. McDonnell
Chief Financial Officer, Executive Vice President
Ginger Gregory
Chief Human Resource Officer, Executive Vice President
Susan H. Alexander
Executive Vice President, Chief Legal Officer, Secretary
Rachid Izzar
Executive Vice President, Head of Global Product Strategy and Commercialization
Adam James Keeney
Executive Vice President, Head of Corporate Development
Nicole Murphy
Executive Vice President - Pharmaceutical Operations and Technology
Priya Singhal
Executive Vice President - Head of Development
Robin C. Kramer
Senior Vice President, Chief Accounting Officer
   
Business Overview
Biogen Inc. is a global biopharmaceutical company focused on discovering, developing, and delivering advanced therapies for people living with serious and complex diseases worldwide. It has a portfolio of medicines to treat multiple sclerosis (MS), spinal muscular atrophy (SMA), Alzheimer's disease, and amyotrophic lateral sclerosis (ALS). It is focused on advancing its pipeline in neurology, specialized immunology, and rare diseases. The Company's marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; SKYCLARYS for the treatment of Friedreich's Ataxia; QALSODY for the treatment of ALS; and FUMADERM for the treatment of severe plaque psoriasis. It also has collaborations for the commercialization of LEQEMBI, ZURZUVAE, RITUXAN, RITUXAN HYCELA, GAZYVA, OCREVUS, LUNSUMIO, and COLUMVI. It commercializes a portfolio of biosimilars of advanced biologics including BENEPALI, IMRALDI, FLIXABI, and BYOOVIZ.
Financial Overview
For the fiscal year ended 31 December 2023, Biogen Inc revenues decreased 3% to $9.84B. Net income decreased 62% to $1.16B. Revenues reflect Rest of World segment decrease of 9% to $4.11B, United States segment decrease of 9% to $3.14B. Net income also reflects G/L on Invest HFS, Maturity & Trading decrease from $1.51B (income) to $0K, Gain on sale of building decrease from $503.7M (income) to $0K.
Employees: 7,570 as of Dec 31, 2023
Reporting Currency: U.S. Dollars
Enterprise value: $37,336M as of Dec 31, 2023
Annual revenue (TTM): $9,836M as of Dec 31, 2023
EBITDA (TTM): $2,545M as of Dec 31, 2023
Net annual income (TTM): $1,161M as of Dec 31, 2023
Free cash flow (TTM): $1,236M as of Dec 31, 2023
Net Debt Last Fiscal Year: $5,888M as of Dec 31, 2023
Shares outstanding: 145,360,798 as of Feb 12, 2024
Index Membership: S&P 500
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.